



PRODUCT: **Pretomanid**

COMPANY: TB Alliance

THERAPEUTIC AREA & INDICATION:

A nitroimidazole drug, one of a class of novel anti-bacterials and approved as a combination with two other drugs for use in patients with highly drug-resistant pulmonary tuberculosis (TB)

ABOUT THE PRODUCT

Patients with highly drug-resistant forms of tuberculosis (TB) have historically been treated with long, complex, toxic and inadequate treatments due to a scarcity of effective medicines. In 2019, TB Alliance's anti-TB drug pretomanid received FDA approval as part of a three-drug, six-month, all-oral regimen for people with highly resistant forms of TB. This regimen (known as "BPaL" and comprised of the drugs bedaquiline, pretomanid and linezolid) has cured nine of out ten patients in the pivotal Nix-TB trial, which is comparable to outcomes with optimal therapy in drug-susceptible TB. Pretomanid is only the third new medicine for drug-resistant tuberculosis to be approved by a stringent regulatory authority in the past 40 years.